Sharekhan

Strides Pharma Science Ltd

Thu 13/03/2025,15:59:32 NSE: STAR

₹ 587.55 -20.85 (-3.43%)
BUY NOW Buy Strides Pharma Science Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Strides Pharma Science Ltd

Thu 13/03/2025,0:0:0

Strides Pharma Science Ltd

Thu 13/03/2025,15:59:32 | NSE : STAR

₹ 587.55-20.85 (-3.43%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 615.75

Previous Close

₹ 608.40

Volume

331961

Mkt Cap ( Rs. Cr)

₹5415.02

High

₹ 615.75

Low

₹ 581.05

52 Week High

₹ 1675.00

52 Week Low

₹ 530.00

Book Value Per Share

₹ 246.48

Dividend Yield

0.42

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Strides Pharma Science Ltd

Your Vote -

Buy

29.46%

Hold

34.96%

Sell

35.58%

29.46%

801 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

587.55

786

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

786

Option Chain

Analyzes market sentiment, predicts Strides Pharma Science Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Strides Pharma Scien - Copy of Newspaper Publication

    18 Feb 2025, 6:38PM Strides Pharma Science Limited has submitted to the Exchange Copy of Newspaper advertisement made regarding dispatch of Postal Ballot Notice dated Jan

  • Strides Pharma Scien - Notice Of Shareholders Meetings-XBRL

    17 Feb 2025, 5:16PM STRIDES PHARMA SCIENCE LIMITED has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot

  • Strides Pharma Scien - Shareholders meeting

    17 Feb 2025, 5:05PM Strides Pharma Science Limited has informed the Exchange regarding Notice of Postal Ballot

  • Strides Pharma Scien - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    17 Feb 2025, 5:01PM Intimation on launch of Postal Ballot

  • Strides Pharma Scien - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Feb 2025, 3:05PM Strides Pharma Science Limited has informed the Exchange about Transcript

  • Strides Pharma Scien - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    4 Feb 2025, 3:19PM Transcript of Earnings Call pertaining to Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2024.

  • Strides Pharma Scien - Copy of Newspaper Publication

    31 Jan 2025, 5:30PM Strides Pharma Science Limited has informed the Exchange about Copy of Newspaper Publication of unaudited financial results for the quarter and nine m

  • Strides Pharma Scien - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    30 Jan 2025, 6:26PM Audio Recording of Earnings call pertaining to the Un-Audited Financial Results for the quarter and nine months ended December 31, 2024

  • Strides Pharma Scien - Analysts/Institutional Investor Meet/Con. Call Updates

    30 Jan 2025, 6:16PM Strides Pharma Science Limited has informed the Exchange about Link of Recording

  • Strides Pharma Scien - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    30 Jan 2025, 5:03PM STRIDES PHARMA SCIENCE LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Trans

  • Strides Pharma Scien - Integrated Filing- Financial

    30 Jan 2025, 4:42PM Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024

  • Strides Pharma Scien - Press Release

    30 Jan 2025, 1:42PM Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 30, 2025, titled ""Press release on Q3 financial resu

  • Strides Pharma Scien - Financial Result Updates

    30 Jan 2025, 1:38PM Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.

  • Strides Pharma Scien - Address Change

    30 Jan 2025, 1:32PM Strides Pharma Science Limited has informed the Exchange regarding change in Registered Office of the company.

  • Strides Pharma Scien - Change in Director(s)

    30 Jan 2025, 1:30PM Strides Pharma Science Limited has informed the Exchange regarding Change in Director(s) of the company.

  • Strides Pharma Scien - Announcement under Regulation 30 (LODR)-Change in Directorate

    30 Jan 2025, 1:30PM Appointment of Ms. Mukta Arora (DIN: 07225715) as Independent Director of the Company effective February 1, 2025.\r\n\r\nChange in designation of Mr.

  • Strides Pharma Scien - Press Release

    30 Jan 2025, 1:28PM Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 30, 2025, titled ""Press release on Q3 FY 25 Financia

  • Strides Pharma Scien - Outcome of Board Meeting

    30 Jan 2025, 1:26PM Strides Pharma Science Limited has informed the Exchange regarding - Outcome of Board meeting held on January 30, 2025 - Financial Results for Q3 of

  • Strides Pharma Scien - Integrated Filing (Financial)

    30 Jan 2025, 4:39PM Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024.

  • Strides Pharma Scien Q3 net profit zooms 488.19% at Rs 14.94 cr

    30 Jan 2025, 2:20PM The company reported standalone net profit of Rs 14.94 crore for the quarter ended December 31, 2024 as compared to Rs 2.54 crore in the same period l

  • Strides Pharma Scien - Announcement under Regulation 30 (LODR)-Change in Registered Office Address

    30 Jan 2025, 1:31PM Change in Registered office of the Company

  • Strides Pharma Scien - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    30 Jan 2025, 1:27PM Strides Reports A Strong Q3FY25 Performance \r\nUpgrade Outlook to Top End of the Range Across Parameters

  • Strides Pharma Scien - Board Meeting Outcome for Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consol

    30 Jan 2025, 1:25PM Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2024

  • Strides Pharma Scien - Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For The Quarter An

    30 Jan 2025, 1:22PM Outcome of Board Meeting - Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024.

  • Strides Pharma Scien - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    24 Jan 2025, 7:59PM Earnings Call for discussion of un-audited financial results for the quarter and nine months ended December 31, 2024.

  • Strides Pharma Scien - Analysts/Institutional Investor Meet/Con. Call Updates

    24 Jan 2025, 7:54PM Strides Pharma Science Limited has informed the Exchange about Schedule of meet

  • Strides Pharma Scien - Board Meeting Intimation

    24 Jan 2025, 6:53PM STRIDES PHARMA SCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 30-Jan-2025 to inter-alia consider and approve the Unaudite

  • Strides Pharma Scien - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulat

    24 Jan 2025, 6:46PM Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 ,inter alia, to consid

  • Strides Pharma Scien - General Updates

    23 Jan 2025, 11:02AM OneSource Specialty Pharma Limited (OneSource) - India s first Specialty Pharma CDMO receives Listing and Trading approval for its Equity Shares from

  • Strides Pharma Scien - Onesource Specialty Pharma Limited (Onesource) - India'S First Specialty Pharma CDMO Receives Listing

    23 Jan 2025, 11:06AM Notification to Stock Exchange

  • Strides Pharma Scien - General Updates

    22 Jan 2025, 11:02AM Strides Pharma debuts with a stellar ESG rating of 76/100 in the S&P Global s Corporate Sustainability Assessment (CSA) 2024

  • Strides Pharma Scien - Strides Pharma Debuts With A Stellar ESG Rating Of 76/100 In The S&P Global's Corporate Sustainabilit

    22 Jan 2025, 11:05AM Notification to Stock Exchange.

  • Strides Pharma Scien - Intimation About Receipt Of Order On Jan 20, 2024 From The Transfer Pricing Officer Being Issued Under

    21 Jan 2025, 6:53PM Notification to Stock Exchange

  • Strides Pharma Scien - Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

    21 Jan 2025, 6:48PM Strides Pharma Science Limited has informed the Exchange regarding receipt of Order on January 20, 2024 from the Transfer Pricing Officer being issued

  • Strides Pharma Scien - Strides Pharma Debuts With A Stellar ESG Rating Of 76/100 In The S&P Global's Corporate Sustainabilit

    22 Jan 2025, 11:05AM Notification to Stock Exchange.

  • Strides Pharma Scien - Strides Pharma Debuts With A Stellar ESG Rating Of 76/100 In The S&P Global's Corporate Sustainabilit

    22 Jan 2025, 11:05AM Notification to Stock Exchange.

  • Strides Pharma Scien - Strides Pharma Debuts With A Stellar ESG Rating Of 76/100 In The S&P Global's Corporate Sustainabilit

    22 Jan 2025, 11:05AM Notification to Stock Exchange.

  • Strides Pharma Scien - Press Release

    20 Jan 2025, 3:00PM Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 20, 2025, titled ""Strides receives USFDA approval fo

  • Strides Pharma Scien - Strides Pharma Debuts With A Stellar ESG Rating Of 76/100 In The S&P Global's Corporate Sustainabilit

    22 Jan 2025, 11:05AM Notification to Stock Exchange.

  • Strides Pharma Scien - Strides Pharma Debuts With A Stellar ESG Rating Of 76/100 In The S&P Global's Corporate Sustainabilit

    22 Jan 2025, 11:05AM Notification to Stock Exchange.

  • Strides Pharma Scien - Strides Pharma Debuts With A Stellar ESG Rating Of 76/100 In The S&P Global's Corporate Sustainabilit

    22 Jan 2025, 11:05AM Notification to Stock Exchange.

  • Strides Pharma Scien - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    20 Jan 2025, 2:51PM Strides receives USFDA approval for Acetaminophen and Ibuprofen Tablets, 125 mg/ 250 mg, expanding the existing OTC portfolio.

  • Strides Pharma Scien has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2024

    17 Jan 2025, 7:30PM As of December 2024, 26.82% is owned by Indian Promoters and 73.18% by Public. <p align=justify> Institutional holds 45.40% (Insurance Companies 4.30%

  • Strides Pharma Scien - Loss/Duplicate-Share Certificate-XBRL

    27 Dec 2024, 3:48PM STRIDES PHARMA SCIENCE LIMITED has informed the Exchange about Issue of duplicate share certificates/Letter of Confirmation

  • Strides Pharma Scien - Loss of Share Certificates

    27 Dec 2024, 3:41PM Strides Pharma Science Limited has informed the Exchange about Loss of Share Certificates

  • Strides Pharma Scien - Trading Window-XBRL

    27 Dec 2024, 10:57AM STRIDES PHARMA SCIENCE LIMITED has informed the Exchange about Closure of Trading Window

  • Strides Pharma Science

    17 Sep 2024 , 10:36AM Strides Pharma receives US FDA approval for Fluoxetine Tabs which is used to treat depression, obsessive-compulsive disorder. (Positive)

  • Strides Pharma arm gets USFDA nod for Theophylline Extended-Release Tablets

    6 Sep 2024 , 10:19AM Theophylline Tablet is used in treatment of Chronic Asthma & Other Chronic Lung Diseases

  • Strides Pharma Science

    6 Aug 2024 , 12:05PM Strides Arcolab International Limited, a wholly owned subsidiary of the Company in UK, proposes to acquire balance stake in Strides Global Consumer Healthcare Limited (Consumer UK) from the existing Investor. Consumer UK is an IP holding entity and is into the business of sale and distribution of pharmaceutical and other over-the-counter consumer health care products, through its subsidiaries in US and India. SAIL UK is currently holding 19% stake in Consumer UK. As at March 31, 2024, carrying value of this investment in the books of SAIL UK is NIL. SAIL UK is acquiring the balance 81% stake from the existing Investor at GBP One. (Positive)

  • Strides Pharma Science

    22 May 2024 , 11:15AM Strides Pharma Science Limited (Strides) today announced that its step down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for the generic version of Sucralfate Oral Suspension, 1gm/10 mL, from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Carafate® 1gm/10mL of AbbVie. Sucralfate is used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers. (Positive)

  • Strides Pharma gets USFDA nod for Sevelamer Carbonate Tablets

    10 May 2024 , 1:28PM Sevelamer Carbonate Tablets, 800 mg has a market size of ~US$ 181 Mn as per IMS

  • Strides Pharma Science

    9 Apr 2024 , 11:00AM Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg . Fluoxetine Tablets approval solidifies the Company's position in the molecule by complementing the existing approval of Fluoxetine capsules. Fluoxetine tablets has a market size of ~US$ 23.9 Mn as per IMS. This approval further strengthens the Company's presence in the Fluoxetine portfolio, complementing the existing approval of Fluoxetine capsules, which has a marketsize of US$106 Mn. The Fluoxetine tablets will be manufactured at the company’sfacility in Puducherry. Fluoxetine is an antidepressant of the Selective Serotonin Reuptake Inhibitor (SSRI) class. It is used for the treatment of Major Depressive Disorder (MDD), Obsessive–Compulsive Disorder (OCD), Bulimia Nervosa, Panic Disorder, with or without Agoraphobia. (Positive)

  • Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg

    9 Apr 2024 , 10:34AM The Fluoxetine tablets will be manufactured at the company's facility in Puducherry.

  • Strides Pharm Science

    8 Apr 2024 , 11:59AM The routine current Good Manufacturing Practices (cGMP) inspection conducted by the United States Food and Drug Administration (USFDA) at the Formulations Facility of Strides Alathur Private Limited, a wholly owned subsidiary of the Company, at Alathur, Chennai during the week of April 1, 2024 to April 5, 2024. The inspection closed with two observations. Company will respond to these observations comprehensively to FDA within the stipulated time.(Neutral)

  • Strides Pharma Science

    1 Apr 2024 , 1:16PM As part of business consolidation and to achieve operational synergy, Strides proposes to consolidate the Group’s South African business under Trinity Pharma (Proprietary) Limited, South Africa. Strides currently operates in South Africa through its subsidiaries Trinity Pharma Ltd., (Trinity) and Strides Pharma (SA) Pty Ltd, South Africa (Strides South Africa). As part of the proposed transaction, Trinity shall acquire 100% stake in Strides SA (60% stake from Strides Cyprus and 40% stake from the other shareholder) by way of a share purchase arrangement. Aggregate consideration for the said acquisition shall be ZAR 21.73 million, which is based on independent valuation. (Positive)

  • Stock Update: Strides Pharma

    7 Mar 2024 , 11:10AM Stock Update: Strides Pharma - Growth stands firm on three pillars.

  • Stock Update: Strides Pharma Q3FY24 Results

    31 Jan 2024 , 11:27AM Stock Update: Strides Pharma Q3FY24 Results - Strong Q3: Beats the guidance

  • Strides Pharma Science bags credit facility worth Rs. 319 mn

    21 Dec 2023 , 2:02PM Strides Pharma says subsidiary Trinity Pharma has availed credit facility from Investec

  • Strides Pharma Science

    21 Dec 2023 , 11:27AM Trinity Pharma Proprietary Limited (Trinity), a step-down subsidiary of the Company in South Africa, has availed credit facility from Investec for Business, a division of Investec Bank Limited, South Africa, for their working capital requirements. In order to facilitate the said borrowing of Trinity, Strides group entities have provided support in the form of Corporate Guarantee/ Letter of Support, amongst others in favour of Investec. Positive

  • Strides Pharma: Strides associate company

    4 Dec 2023 , 11:56AM Stelis Biopharma announces closure of its transaction with Syngene International Limited. Stelis has received today (1 December, 2023) a payment of INR 3,950 Million and the balance amount shall be received on completion of certain post-closing actions and final adjustments, if any which is expected in December 2023. This will support our increased focus for Mammalian Drug Substance opportunities in the CDMO space. With its current installed capacity of 8,000 litres, the near term expanded capacity at 28,000 litres will make Stelis a significant player in the space. (Positive)

  • Strides Pharma Science

    4 Dec 2023 , 10:30AM Strides launches Icosapent Ethyl Acid Soft Gel Capsules in partnership with Amneal. Strides Pharma Science Limited (“Strides”) and Amneal Pharmaceuticals, Inc. today announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA. The product has been in-licensed from Strides, a global pharmaceutical manufacturer, and will be commercialized by Amneal starting in the fourth quarter of 2023. (Positive)

  • Strides Pharma Science

    23 Nov 2023 , 11:57AM Strides receives USFDA approval for Generic Suprep Bowel Prep Kit. STRIDES is the second Generic to get approval for this key product and the approval solidifies the Company's leading position in bowel preparation products. The Product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Suprep Bowel Prep Kit Oral Solution 17.5g/ 3.13g/ 1.6g per 6 ounces of Braintree Laboratories Inc. (Braintree). The Product has a market size of ~US$143 Mn per IQVIA. The Product will be manufactured at the company’s facility in Bengaluru (Positive).

  • Strides Pharma arm gets USFDA nod for Levetiracetam Oral Solution

    21 Nov 2023 , 12:07PM Levetiracetam is used to help control certain types of seizures

  • Strides Pharma Q2FY24 results

    30 Oct 2023 , 1:43PM Strides Pharma Q2FY24 results – Healthy numbers on an adjusted basis

  • Strides Pharma

    30 Oct 2023 , 1:07PM Strides announces sale of manufacturing facility in Singapore for a consideration of $15m. As part of manufacturing network cost optimization, Strides had last year mothballed the Singapore manufacturing operations. With the acquisition and successful integration of Chestnut Ridge site in US, the Singapore site has been made redundant in the Strides network. Transaction to be EPS accretive immediately with reduction of ~$9m (~₹750m) in annual costs with no impact on Revenues. Transaction closure expected in Q3FY24, proceeds to be used for Debt Reduction. (Positive)

  • Strides Pharma Sciences

    5 Oct 2023 , 1:17PM Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets. The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Atripla Tablets of Gilead Sciences LLC. The EET tablet has a market opportunity in the US of ~US$ 7.5Mn per IQVIA.

  • Stock update: Strides Pharma

    27 Sep 2023 , 10:59AM Stock update: Strides Pharma – Demerger to unlock value for the shareholders, Earnings recovery remains the key

  • Strides Pharma Demerger Concall highlights:

    26 Sep 2023 , 10:46AM Strides Pharma Demerger Concall highlights:

  • Strides Pharma Science

    25 Sep 2023 , 10:09AM Strides Pharma arm gets USFDA Nod For Ethyl Capsules. Icosapent Ethyl Capsule is used to reduce the risk of Heart Attacks, Strokes. This product has a market size of US$ 1.3 bn as per IQVIA.This product will be manufactured in Bangalore facility. Positive read thru.

  • Strides Pharma Science

    18 Sep 2023 , 10:40AM The company has announced that its step‐ down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received tentative approval for its New Drug Application (NDA) 505b2 of Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate 50mg/ 300mg/ 300mg tablets from the United States Food & Drug Administration (USFDA). Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate 50mg/ 300mg/ 300mg tablets is a complete regimen for treatment of HIV‐1 infection in adults and pediatric patients weighing at least 35kgs. The Product will be manufactured at the company’s facility in Bengaluru. It is estimated that the value of procurement for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate 50mg/ 300mg/ 300mg tablets is ~650mn USD. Positive for the stock.

  • Strides Pharma to take 100% stake in step-down subsidiary

    7 Sep 2023 , 11:16AM To acquire 100% stake in Strides Pharma Services from Arco Lab

  • Stelis Biopharma enters into a binding term sheet with Syngene International

    5 Jul 2023 , 9:59AM Stelis Biopharma enters into a binding term sheet with Syngene International to divest its Unit 3 multi-modal facility for a gross consideration of Rs. 7,020 mn

  • Strides Pharma and Biocon

    5 Jul 2023 , 9:08AM Strides Pharma has entered into a binding agreement with Syngene International to divest its subsidiary Stelis Biopharma’s (a biologics and sterile injectable CDMO player) manufacturing facility at Bommasandra Industrial Area, Bengaluru, India (Unit III) to Syngene International Ltd. (Biocon Ltd.’s contract research services arm) in a slump sale at Rs. 702 Cr. which will be paid in cash and likely to close within 90 days. Stelis will continue to operate its Unit 1 and Unit 2 in Bengaluru. Strides Pharma repaid Rs. 470 Cr of gross debt at Stelis and Rs. 720 Cr for the group in total in FY23. Stelis Biopharma reported net loss of Rs. 126 Cr in Q4FY23 and Rs. 800 Cr in FY23 on account of write-downs of inventory related to Covid 19, operating losses and impairment of intangibles with its products.

  • Strides Pharma Science

    3 May 2023 , 9:08AM Strides Pharma and Orbicular Pharma Technologies Pvt Ltd. informed that they have entered in-to a strategic partnership to develop, manufacture, and commercialise nasal sprays for the global markets. Orbicular, a specialty pharma company, will use its expertise to develop nasal sprays for the global markets. Strides will commercialise these nasal sprays across the markets, using its commercial infrastructure in the US, Europe and other markets. The products will be manufactured at Strides’ Chestnut Ridge, New York facility. Under the partnership the duo will be commercialising 4 nasal sprays with a combined global IQVIA estimated market size of USD 400 million. Positive read through for the stock.

  • Strides flagship facility in Bangalore receives USFDA inspection closure

    24 Feb 2023 , 10:25AM USFDA issues establishment inspection report for company's #angalore facility

  • Strides Pharma

    15 Feb 2023 , 2:52PM Strides Pharma’s promoter’s pledged shares have increased by 0.04% and 0.94% towards Kotak Securities and Motilal Oswal Finvest Ltd., respectively, making its pledged shares increase to 77.32% of the total promoters shareholding of 31.04%. Neutral to marginally negative read through for the stock.

  • Strides Pharma Q3FY23 Results

    24 Jan 2023 , 3:27PM Strides Pharma Q3FY23 Results-: Beat on EBITDA while disappoints on revenue and net income front

  • Strides Pharma Science

    23 Jan 2023 , 12:40PM Strides Pharma has successfully completed inspection of WHO at its Puducherry facility carried out between 16-20 January 2023. It’s a positive read through for the stock.

  • Stelis Biopharma's flagship facility gets EIR from USFDA

    18 Jan 2023 , 11:15AM Strides Pharma's biologics arm Stelis Bio’s Bangalore facility gets EIR from USFDA for a drug-device combination

  • Stelis Biopharma

    18 Jan 2023 , 10:50AM Stelis Biopharma Ltd., an emerging biopharma CDMO and the biologics arm of Strides Pharma Sciences Ltd. has announced that it has received EIR from the USFDA specific to drug device combination products to be commercialized at Stelis’ flagship facility in Bengaluru, India.

  • Strides Pharma Sciences

    28 Dec 2022 , 2:25PM Stelis Biopharma Ltd. (the biopharma CDMO company) and the biologics arm of Strides Pharma Sciences Ltd. announced that Stelis Biopharma has received an approval for a key ANDA from the USFDA. The filing for the ANDA was done by Stelis Biopharma from Bangalore facility, which has high end automated Drug Product (DP) lines, integrated with isolators to convert drug substances (DS) into stable formulations to fill finished dosages within the same facility in all injectable forms. The facility had recently received Establishment Inspection Report (EIR) from the USFDA for DP. Stelis will manufacture and commercially supply the product from Bangalore. Our view: Positive read through for the stock

  • Stelis Biopharma's CDMO partner receives approval for a key ANDA from the USFDA

    28 Dec 2022 , 2:21PM Stelis will manufacture and commercially supply the product to its CDMO partner from its flagship facility in Bangalore, India

  • Strides Pharma Science

    22 Dec 2022 , 12:29PM Strides Pharma’s Singapore based subsidiary, Strides Pharma Pte Limited, has received AUD 94 million (Rs. 525 Cr) as the deferred consideration for the sale of the company’s Australian operations in 2019. The proceeds are planned to be utilized towards deleveraging balance sheet. Strides had existed its Australia operations for AUD 394 million (Rs. 2,200 Cr) in 2019 when it had received the AUD 300 million (Rs. 1,675 Cr). Despite exiting from Australia operations, Strides continues to remain the preferred supplier to Arrotex, which is the largest generic company in Australia. Our View: Positive.

  • Strides Pharma Singapore arm gets deferred consideration for Australian operations

    22 Dec 2022 , 11:49AM Strides Pharma Singapore arm gets deferred consideration of Rs. 525 cr for Australian operations sale in 2019

  • Strides Pharma Science

    19 Aug 2022 , 9:37AM Strides Pharma Science: step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, has received USFDA approval for Naproxen Sodium Softgel Capsules, 220 mg (OTC). Strides is focusing on building a private label business in the US by leveraging its portfolio of products across soft gels, tablets, capsules and other formats. The approval for Naproxen Sodium OTC Softgel Capsules further strengthens Strides OTC portfolio for the US markets. The addressable market size is $ 100 mn for the product which is quiet healthy and hence the approval is positive.

  • Strides Pharma receives USFDA approval for Naproxen Sodium OTC Softgel capsules

    18 Aug 2022 , 3:24PM Naproxen Sodium is used to help relieve pain due to Arthritis

  • Strides Pharma Sciences

    4 Aug 2022 , 10:23AM Strides Pharma Sciences: Step down subsidiary - Strides Pharma Global Pte. Limited, Singapore gets USFDA approval for Cyclosporine Softgel Capsules USP (Modified), 25 mg, 50 mg, and 100 mg. Cyclosporine Softgel Capsules is part of Strides niche product portfolio with limited competition in the US market and further strengthens immunosuppressant portfolio for the US markets which now comprises of Mycophenolate Mofetil tablets and capsules, Tacrolimus capsules and Cyclosporine Softgel Capsules. the US market for Cyclosporine Capsules USP is $91 mn, which is healthy and is positive read thru.

  • Strides Pharma receives USFDA approval for Cyclosporine Softgel capsule

    3 Aug 2022 , 12:40PM Cyclosporine Softgel capsule is used to prevent organ rejection during a transplant

  • Strides Pharma Sciences

    26 Jul 2022 , 9:45AM The committee of the board of directors in a meeting have approved raising of Rs 150 crore through issue of 1500 senior secured rated unlisted redeemable and Non-Convertible Debentures on private placement basis with face value Rs. 10,00,000 aggregating to Rs 150 crore.

  • Strides Pharma Sciences

    21 Jul 2022 , 2:39PM Meeting of the Committee of Board of Directors is scheduled on July 25, 2022, to consider and approve raising of funds by way of issuance of Non-Convertible Debentures on a private placement basis.

  • Strides Pharma announces results from phase ii/iii clinical trial in India

    24 Jun 2022 , 11:13AM Strides Pharma announces results from phase ii/iii clinical trial in India of SARS-CoV-2 vaccine, AKS-452

  • Stelis Biopharma's 2 Biologics manufacturing facilities receive EU cGMP Accreditation

    16 Jun 2022 , 9:42AM GMP approval was received both for the flagship facility and small-scale commercial and clinical batch manufacturing facility.

  • Strides Pharma Science

    13 Jun 2022 , 10:20AM Recalling over 6,78,829 bottles of blood pressure lowering drug - Losartan Potassium tablets in the US market in multiple strengths due to deviation from standards. The USFDA has classified this recall as a class II recall due to deviations for CGMP. As the USFDA has classified this as a Class II recall it is unlikely to have any material impact on the financial performance of the company.

  • Strides receives USFDA approval for Ibuprofen OTC Oral Suspension

    10 Jun 2022 , 3:37PM Ibuprofen OTC Oral Suspension is used to relieve muscular pain

  • Strides receives USFDA approval for Ibuprofen Oral Suspension

    30 May 2022 , 9:48AM The products to be marketed by Strides Pharma Inc. in the US market

  • Strides Pharma

    21 Mar 2022 , 10:49AM Akston Biosciences Corporation and Biolexis, a division of Stelis Biopharma, have entered into a licensing, manufacturing and commercialization agreement for Akston’s AKS-452 (COVID-19 vaccine, which is room temperature stable). Under the agreement, Biolexis gains the right to manufacture and commercialize the vaccine in India and over 130 LMIC countries. Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relation. Positive read thru

  • Strides partners with Medicines Patent Pool

    21 Mar 2022 , 9:41AM Strides Pharma partners Medicines Patent Pool (MPP) to commercialize the generic version of Pfizer’s COVID-19 Oral Treatment across 95 markets

  • Strides Pharma

    15 Mar 2022 , 10:51AM The company had on 10th February 2022 announced to raise funds by way of preferential issue to Promoters entity. – Karuna Business Solutions. The promoters’ initial intent was to subscribe for warrants to be able to acquire up to 4 mn shares in the company. Further to this, and considering prevailing global external factors, the promoters have revised their intent down to subscribe to up to 2 mn equity warrants at Rs 442 per warranty and the price is higher than the floor price

  • Strides receives USFDA approval for Colchicine Tablets

    11 Mar 2022 , 10:43AM Strides Pharma gets USFDA approval for Colchicine Tablets, used for the treatment and prevention of gout

  • Strides Pharma Sciences

    21 Jan 2022 , 10:23AM Along with its Subsidiary Universal Corporation Limited Kenya, has entered in to a partnership with Medicines Patent Pool (MPP) to commercialize oral anti –Covid drug, Molnupiravir in the international markets. The partnership is a voluntary non‐exclusive sub‐license partnership with MPP covering 105 countries as part of MSD and MPP’s initiative to improve the access for Molnupiravir across countries. In December 2021 Strides received an Emergency approval from the DCGI to launch Molnupiravor (200 mg) in India. Given the increasing no of cases globally, the demand for Molnupiravor is expected to be on the higher side and hence offers substantial growth potential for Strides. Positive

  • Strides Pharma partners medicines patent pool to commercialise molnupiravir for global markets

    20 Jan 2022 , 3:45PM Strides and its African subsidiary Universal Corporation partner with Mpp to commercialize molnupiravir for the global markets

  • Strides Pharma Science

    18 Jan 2022 , 9:44AM Strides Pharma Global Pte. Limited, Singapore, a step down wholly owned subsidiary company has received USFDA approval for for Oseltamivir Phosphate for Oral Suspension,6 mg/mL (Reference listed drug (RLD) – Tamiflu), used for treating flu / influenza. The addressable market size in US for Oseltamivir Phosphate for Oral Suspension stands at $132 mn, which is a sizeable, hence approval is positive.

  • Stelis Biopharma commissions vaccine manufacturing facility at Bengaluru

    21 Dec 2021 , 1:39PM Stelis also receives an initial Export No Objection Certificate (NOC) from CDSCO

  • Strides Pharma Sciences

    21 Dec 2021 , 10:34AM Biotech arm – Stellis Biopharma Limited (stellis) has commissioned its large-scale fully integrated vaccine manufacturing facility at Bengaluru, post CDSCO Central Drugs Standard Control Organization) inspection. Stelis' greenfield vaccine facility is one of the largest viral vector manufacturing sites with a bespoke design for producing the Russian Sputnik Vaccine and also offers flexible technologies for manufacturing lentivirus, adenovirus and retrovirus products/ vaccines. The drug block of the facility is designed to produce 720 mn doses a year. Stelis has also received an initial Export No Objection Certificate (NOC) from CDSCO to export up to 50 million doses of the Sputnik Light vaccine and the company is one track to commercialize this vaccine for Global markets in Q4FY22, hence positive.

  • Stock Update: Strides Pharma Science

    11 Nov 2021 , 12:11PM Stock Update: Strides Pharma Science - Q2FY22 results review: Disappointing Q2; Revival seems at a distance

  • Strides Pharma Sciences closes plant buy deal

    21 Oct 2021 , 11:32AM Deal closure would help Strides fast-track product launch strategy

  • Strides PharmaScience – Q1FY22 Result Update

    10 Aug 2021 , 9:13AM Strides PharmaScience – Q1FY22 Result Update: Disappointing Q1; Downgrade to Hold

  • Strides Pharma Sciences Q1FY22

    6 Aug 2021 , 2:43PM Covid led disruptions impacts performance severely across regions, results way below estimates

  • Strides Pharma Science

    6 Aug 2021 , 10:43AM Strides Pharma: wholly owned subsidiaries have entered into definitive agreements with subsidiaries of Endo International plc to acquire its manufacturing facility at Chestnut Ridge, New York including a basket of ANDA’s for a consideration of US$24 mn (~RS 180 cr) funded through a mix of internal funds and debt. The acquisition would fortify Strides’ Pharmas presence in the US which constituted around 48% of FY2021 revenues through acquisition of a multi dosage facility in the US and a basket of ANDAs across multiple therapeutic segments. The cumulative addressable market for the acquired portfolio is US$4.7bn as per IQVIA MAT MAY 2021. The facility has annual capacity of 2 billion units across semisolids, liquids, nasal sprays along with oral solids and has requisite regulatory approvals from the USFDA and Drug Enforcement Administration (EDA), which allows for manufacturing controlled substances as well.

  • Strides inks definitive agreement with Endo

    6 Aug 2021 , 9:12AM Strides inks definitive agreement with Endo to acquire its manufacturing facility in the US along with basket of ANDAs

  • Strides Pharma Sciences

    28 Jun 2021 , 10:30AM Strides Pharma Sciences: The company’s Puducherry plant has successfully completed the EU GMP inspection carried out by the National Institute of Pharmacy and Nutrition (OGYÉI), Hungry and the company has now received a GMP certification, thereby confirming the successful closure of the inspection. The Puducherry facility caters to the US and Other Regulated Markets and Institutional businesses and has capabilities to produce finished dosage formulation products across multiple dosage formats. The receipt of the GMP certification is positive as it offers potential growth opportunities for the company.

  • Strides announces successful completion of EU GMP inspection at Puducherry facility

    28 Jun 2021 , 10:21AM Company receives the renewed GMP certificate thereby confirming the successful closure of the inspection

  • Strides Pharma arm inks deal for making oral COVID drug

    15 Jun 2021 , 3:32PM Exclusive partnership signed with Ennaid Therapeutics

  • Strides Pharma Science – Q4FY21 Result Update

    28 May 2021 , 10:59AM Strides Pharma Science – Q4FY21 Result Update: Long-term growth levers intact despite near-term blips

  • Strides Pharma Sciences Q4FY2021

    27 May 2021 , 3:19PM Strides Pharma Sciences Q4FY2021 – Strong quarter, results missed estimates.

  • Strides Pharma

    26 May 2021 , 11:41AM Biotech Business – Stellis Pharma has concluded its Series C fund raise amounting to $125 mn. The current capital raise would enable stellis to pursue its growth initiatives including accelerating the vaccine block infrastructure. Consequent to the above transaction, Strides stake in Stelis now stands at 37.09% against 54.48% earlier. Also this points at a possible value unlocking for strides shareholders as it looks to de-merge and list the Stellis business on a standalone basis. We now have a buy recommendation on the stock.

  • Strides Pharma Sciences

    23 Apr 2021 , 11:15AM Strides Pharma Sciences: As per media reports the promoters of Strides Pharma Sciences are in talks with PE players – Carlyle, KKR, Advent and Baring Asia to buy the promoters stake in company. The promoters hold 29.67% stake in the company valued at ~ Rs 2500 cr.

  • Strides Pharma Science

    15 Mar 2021 , 11:50AM Strides Pharma Sciences: Wholly owned subsidiary - Strides Pharma Global Pte. Limited, Singapore gets USFDA approval for Potassium Chloride for Oral Solution USP, 20 mEq. Potassium Chloride Oral Solution is indicated for the treatment and prophylaxis of hypokalemia n patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient. As per IQVIA January MAT 2021, the US market for the drug is approximately US$ 56 Mn. The approval is positive as it would add to the US sales growth.

  • Strides gets USFDA nod for Potassium Chloride for Oral Solution

    15 Mar 2021 , 11:32AM Potassium chloride is used to prevent or to treat low blood levels of potassium (hypokalemia)

  • Strides gets USFDA nod for Ibuprofen OTC Oral Suspension

    24 Feb 2021 , 10:51AM Strides Pharma gets USFDA nod for Ibuprofen OTC oral suspension. It is an everyday painkiller for a range of aches & pains

  • Strides Pharma Sciences Q3FY2021

    4 Feb 2021 , 2:46PM Strides Pharma Sciences Q3FY2021 – Weak operational performance, results missed estimates

  • Strides receives USFDA approval for Ursodiol Capsules

    25 Jan 2021 , 1:03PM Strides Pharma gets USFDA nod for Ursodiol Capsules, indicate for the treatment of patients with Primary Biliary Cirrhosis

  • Strides Pharma Science

    22 Jan 2021 , 12:31PM Strides Pharma Science: Ratings agency - India Ratings and Research has upgraded the companys long term Issuer Rating to ‘IND A+’ with a stable outlook as compared to ‘IND A’ assigned previously. The upgrade of the ratings is positive.

  • Strides Pharma Science

    15 Jan 2021 , 10:16AM Strides Pharma Sciences: Subsidiary company - Strides Pharma Global Pte. Limited, Singapore gets USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg. The drug is used to treat HIV patients. As per IQVIA MAT November 2020, the US market for the drug stands at around $2.4bn. The approval is positive considering the substantial market size of the drug and would also help grow the US sales which is around 56% of FY2020 overall sales.

  • Strides Pharma gets USFDA nod for anti-HIV drugs

    15 Jan 2021 , 10:11AM Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets

  • Strides Pharma Science promoters seek exit

    30 Dec 2020 , 11:39AM Promoters currently hold a 29.69% stake

  • Strides receives USFDA approval for Oxybutynin Chloride Tablets

    18 Dec 2020 , 2:43PM Strides Pharma receives USFDA approval for Oxybutynin Chloride tablets used for the treatment of overactive bladder and urinary conditions

  • Strides Pharma Science: Stock Update

    11 Dec 2020 , 9:11AM Strides Pharma Science: Stock Update - Set to take a long Stride

  • Strides Pharma Science

    23 Nov 2020 , 3:15PM Get USFDA approval for Prednisone Tablets USP - 2.5 mg and 5 mg. it is used in treatment of different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders. The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Deltasone Tablets. According to IQVIA MAT September 2020 data, the US market for Prednisone Tablets is approximately $30 Mn. As of FY2020 the US accounted for ~55% of the company’s sales. The approval is positive as it would add to the US sales.

  • Strides receives USFDA approval for Prednisone Tablets

    23 Nov 2020 , 3:05PM Strides Pharma gets nod for Prednisone Tablets USP, 2.5 mg and 5 mg from the USFDA

  • Strides Pharma Science: Q2FY21 Result Update

    30 Oct 2020 , 11:15AM Strides Pharma Science: Q2FY21 Result Update – Soft Quarter; robust growth outlook

  • Strides Pharma Sciences: Weak performance

    29 Oct 2020 , 2:12PM Strides Pharma Sciences: Weak performance; results miss estimates

  • Strides Pharma Science

    20 Oct 2020 , 12:31PM Strides Pharma: gets final approval from the USFDA for Ethacrynic Acid Tablets USP - 25 mg.The product is a generic version of Edecrin tablets 25 mg, which has sales of $14mn in the US as per IQVIA MAT August 2020. The product will be manufactured at the company’s Bangalore facility at Bengaluru and will be marketed by subsidiary - Strides Pharma Inc. in the US market. The approval is positive as it would add to the US revenues

  • Strides receives USFDA approval for Ethacrynic Acid Tablets

    20 Oct 2020 , 11:06AM Used to treat high blood pressure and the swelling caused by diseases like congestive heart failure, liver failure, and kidney failure

  • Strides Pharma Sciences: Viewpoint Update

    1 Oct 2020 , 12:09PM Strides Pharma Sciences: Viewpoint Update - Set for impressive earnings growth

  • Strides Pharma

    23 Sep 2020 , 10:10AM As per media news the company has got USFDA approval for NSAID Mefenamic Acid. It is a non-steroidal anti-inflammatory drug. The approval is positive as it would add to the US sales, which account for around 55% of the overall sales

  • Strides Pharma Science

    22 Sep 2020 , 2:19PM Strides Pharma: Gets USFDA approval for Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg. The product is bioequivalent and therapeutically equivalent to Butalbital, Acetaminophen, and Caffeine Tablets Actavis Laboratories FL Inc. As per IQVIA MAT July 2020, the bioequivalent tablets clocked a USD 40 mn sales in the US markets. The approval is positive as it would add to the US sales.

  • Strides receives USFDA approval for Butalbital, Acetaminophen, and Caffeine Tablets

    22 Sep 2020 , 12:04PM The product will be marketed by Strides Pharma Inc. in the US market

  • Strides Pharma Science

    21 Sep 2020 , 12:18PM Sequent Scientific which is one of the promoter group entities holding 3.7% stake in the company has transferred its holdings to Pronomz Ventures, which is also a part of the promoters group. The proposed price for acquisition is Rs 475 per share. Post this Pronomz Ventures stake in Strides will increase to 17.84% from 14.14%.

  • Strides Pharma Science

    15 Sep 2020 , 10:11AM Announced that it would re enter the sterile injections business and has launched SteriSciences as its injectable platform. The company has incorporated a new entity SteriSciences Pharma Pvt Ltd for the injectibles business and would invest Rs 135 cr over the next 24 months This is positive as it would aid the overall topline growth

  • New Idea - Strides Pharma Sciences

    2 Sep 2020 , 11:01AM New Idea - Strides Pharma Sciences: Viewpoint - Set for phenomenal growth

  • Strides receives USFDA approval for Ursodiol Tablets

    21 Aug 2020 , 11:06AM Product to be launched immediately to be marketed by Strides Pharma Inc. in the US market

  • Strides Pharma successful completes of UK MHRA inspection Puducherry facility

    19 Aug 2020 , 2:23PM Successful completion of the inspection carried out by the UK MHRA at its Puducherry facility

  • Strides Pharma share price gains on USFDA approval

    9 Jul 2020 , 9:56AM Strides receives USFDA approval for Butalbital,Acetaminophen, Caffeine, and Codeine Phosphate Capsules

  • Strides Pharma Science

    3 Jul 2020 , 10:17AM As per media news, the company gets US FDA nod for generic of Gilenya capsule. The drug is used in the treatment of multiple sclerosis-MS. The USFDA approval is positive.

  • Strides receives USFDA approval for Triamcinolone Acetonide Ointment

    2 Jun 2020 , 11:01AM The product is part of the niche and small volume product portfolio with limited competition in the US market

  • Strides Pharma develops and commences export of Favipiravir Antiviral tablets

    29 Apr 2020 , 9:50AM Strides is the first Indian Company to have commenced export of Favipiravir tablets

  • Strides receives USFDA nod for Flucytosine Capsules

    20 Apr 2020 , 10:08AM Flucytosine Capsule is indicated only in the treatment of serious infections caused by susceptible strains of Candida

  • Strides Pharma successful completes USFDA inspection at Bangalore Unit

    30 Mar 2020 , 10:01AM Strides announces successful completion of USFDA inspection conducted in January 2020 at flagship facility in Bangalore

  • Strides Pharma gets EIR from USFDA

    26 Mar 2020 , 10:32AM EIR from USFDA on continued GMP status for the flagship facility in Bangalore

  • Strides receives USFDA approval for Tetracycline Hydrochloride Capsules

    4 Mar 2020 , 10:28AM Strides Pharma gets US FDA nod for antibiotic Tetracycline Hydrochloride capsules

  • Strides inks deal with Pharmaceutics International

    7 Feb 2020 , 11:27AM Strides to acquire 18 ANDAs from Pharmaceutics International, Inc.

  • Strides gets USFDA tentative nod for Triamcinolone Acetonide Ointment

    24 Jan 2020 , 11:23AM The product approval from flagship facility in Bangalore to be marketed by Strides Pharma Inc

  • Strides Pharma Science gets EIR from USFDA

    20 Jan 2020 , 11:21AM Strides announces successful closure of the USFDA inspection at its manufacturing site in Florida, United States

  • Strides Pharma gets USFDA nod for an allergy drug

    16 Jan 2020 , 10:50AM Strides receives USFDA approval for Loratadine OTC Softgel Capsules

  • Strides receives USFDA tentative nod for Diclofenac Potassium Softgel Capsules

    4 Dec 2019 , 11:06AM The product is a generic version of Zipsor Capsules, 25 mg, of Assertio Therapeutics, Inc

  • Strides Pharma relaunches Ranitidine tablets in US

    8 Nov 2019 , 1:52PM Relaunch of Ranitidine tablets for the US market

  • Strides Pharma gets USFDA nod for Solifenacin Succinate Tablets

    27 Sep 2019 , 10:35AM Strides Pharma's Singapore arm receives approval for Solifenacin Succinate Tablets, generic version of Vesicare from USFDA

  • Strides Pharma suspends sale of Ranitidine tablets in the US market

    27 Sep 2019 , 10:14AM Strides Pharma suspend sales of ranitidine tablets in the US market until such time it has clarity of next steps as would be indicated by the USFDA

  • Strides acquires USFDA approved manufacturing facility in US

    27 Aug 2019 , 11:21AM Strides Pharma Science acquires a USFDA approved manufacturing facility in Florida

  • Strides inks JV pact with China's Sihuan Pharma

    30 Jul 2019 , 11:06AM Strides Pharma enters into JV with China's Sihuan Pharmaceutical Holdings Group

  • Strides Pharma successful completes USFDA inspection

    22 Jul 2019 , 1:32PM Strides Pharma: Company has successful completion of USFDA inspection at its key facility in Bangalore, with a Voluntary Action Indicated (VAI) classification – Positive read thru.

  • Strides Pharma- USFDA Warning Letter to Strides Puducherry points to data integrity. Warning letters says, uncontrolled destruction of CGMP records, lack of adequate documentation practice. Discarded CGMP documents and evidence of uncontrolled sheddi

    17 Jul 2019 , 10:26AM Strides Pharma- USFDA Warning Letter to Strides Puducherry points to data integrity. Warning letters says, uncontrolled destruction of CGMP records, lack of adequate documentation practice. Discarded CGMP documents and evidence of uncontrolled shedding of documents-Negative read-thru

  • Strides Pharma Science up on sale of investments in Arrow

    1 Jul 2019 , 11:02AM Strides Pharma Science gets approval for the sale of its investment in Arrow

  • Strides to launch Potassium Chloride ER Tablets in US market

    2 Apr 2019 , 9:51AM Strides Pharma launches potassium chloride extended-release tablets in the US Market

  • Strides gets USFDA nod for its greenfield oral dosage facility

    27 Mar 2019 , 2:17PM Singapore oral dosage facility – For growth capacities

  • Strides gets USFDA nod for Ethosuximide Softgel Capsules

    20 Feb 2019 , 12:07PM Strides receives USFDA approval for Ethosuximide Softgel Capsules

  • Strides gets USFDA nod for intermediate-acting synthetic drug

    13 Feb 2019 , 10:17AM Strides Pharma receives USFDA approval for Triamcinolone Acetonide Cream

  • EIR from USFDA on continued GMP status for the flagship facility in Bangalore

    6 Feb 2019 , 10:40AM Strides Pharma gets EIR (Establishment Inspection Report) from USFDA (inspection concluded with zero obs) on continued GMP status for facility in Bangalore – Positive; The facility is the largest for company and supports several current and future products for the US markets; the facility manufacturers tablets, capsules, liquids, creams ointments & sachets.

  • Strides, Mylan to release General Claims Escrow on Agila transaction

    19 Dec 2018 , 10:32AM Strides will receive ~ US$ 42 Mn towards full and final release of the General Claims Escrow immediately

  • Strides receives USFDA approval for Lidocaine Ointment

    13 Dec 2018 , 10:07AM Strides Pharma Science rises over 3% to Rs. 478, after its subsidiary receives approval for Lidocaine Ointment USP 5% from the USFDA

  • Strides Vivimed JV gets nod for Albendazole Tablets

    11 Dec 2018 , 10:30AM Strides-Vivimed joint venture receives USFDA approval for Albendazole tablets

  • Strides Pharma partners with SUDA Pharma in US

    9 Nov 2018 , 3:03PM Strides Pharma enters into a strategic partnership with SUDA Pharmaceuticals for the US market

  • Strides Pharma falls on USFDA inspection

    19 Sep 2018 , 11:34AM Strides Pharma slips over 5% to Rs472.4, after USFDA issues Form 483 with three observations

  • Strides Pharma falls on USFDA inpection

    19 Sep 2018 , 11:34AM Strides Pharma slips over 5% to Rs472.4, after USFDA issues Form 483 with three observations

  • Strides Shasun gets nod for Ketoconazole Tablets

    19 Jun 2018 , 10:55AM Strides Shasun receives final approval for Ketoconazole Tablets USP, 200 mg from the United States Food & Drug Administration (USFDA)

  • Strides Shasun gets USFDA nod for flu treatment

    12 Jun 2018 , 11:27AM Strides Shasun announces its unit receive final approval from the US drug regulator for Oseltamivir Phosphate capsules

  • Strides Shasun gains on USFDA nod for Efavirenz Tablets

    14 Mar 2018 , 11:44AM Strides Shasun rises over 2% at Rs693.05, after receiving USFDA approval for Efavirenz Tablets

  • Strides Shasun buys stake in Trinity Pharma

    20 Dec 2017 , 12:31PM Strides Shasun enters into definitive agreement with Trinity Pharma, South Africa (Trinity) for acquisition of controlling stake in Trinity

  • Strides Shasun gets nod from USFDA for Acetazolamide tablets

    22 Nov 2017 , 10:48AM Strides Shasun receives US drug regulator's approval for Acetazolamide tablets

  • Strides gets USFDA nod for Omega-3-Acid Ethyl Esters capsules

    20 Sep 2017 , 12:40PM Strides Shasun rises over 3% to Rs1040.8, after receiving approval from USFDA for Omega-3-Acid Ethyl Esters Softgel capsules, a generic version of Lovaza
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Strides Pharma Science Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 5155.301 4804.255 4651.315 4089.098 4027.624
Liabilities 5155.301 4804.255 4651.315 4089.098 4027.624
Equity 91.9 90.303 89.79 89.681 89.565
Gross Profit 255.276 98.477 76.63 187.32 210.036
Net Profit 65.491 4.682 180.188 78.24 111.699
Cash From Operating Activities -35.756 241.74 -282.685 282.762 148.838
NPM(%) 3.04 0.25 9.1 4.21 6.67
Revenue 2153.258 1854.496 1979.003 1857.566 1674.149
Expenses 1897.982 1756.019 1902.373 1670.246 1464.113
ROE(%) 2.88 0.2 7.93 3.44 4.91

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
09 Sep 2024 2.5 25 0.43 899.55
05 Aug 2021 2.5 25 0.43 807.75
24 Jul 2020 2 20 0.43 421.15
22 Aug 2019 12 120 0.43 352.75
19 Jul 2019 3 30 0.43 484.45
12 Sep 2018 2 20 0.43 387.05
07 Sep 2017 4.5 45 0.43 1027.6
21 Jul 2016 4 40 0.43 1191.5
22 Jul 2015 3 30 0.43 1194.95
16 Oct 2014 105 1050 0.43 740.95
01 Sep 2014 5 50 0.43 537.3
30 May 2013 2 20 0.43 917.25
14 May 2012 2 20 0.43 534.65
18 May 2011 1.5 15 0.43 342.9
21 May 2010 1.5 15 0.43 298.7
12 Jun 2007 2 20 0.43 360.1
13 Jun 2005 1.5 15 0.43 193.75
0 20 0.43 710.85

Peers

Other companies within the same industry or sector that are comparable to Strides Pharma Science Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 334.47 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 1218.77 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 628.20 2.31 0.00
Astec Lifesciences Ltd 653.90 -5.55 0.00 1149.19 -239.30 0.00

Company Info

2002 -Board approves for the allotment of 210,955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd. -Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route. -Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act. -Incorporates 'Strides Africa Ltd' at British Virgin Island with an authorised capital of US $ 200,000 as 100% wholly owned subsidiary. -Board decides to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations. 2003 -Nominates Mr Francis Pinto as the Director on the Board of the company. -Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems. -Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical products. -Changes in the Management: Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr Krishna Kumar Menon as COO. -Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company. -Strides inks MoU with Ribbon SRL for Cephalosporin 2004 -Major Fire occurs in Private Custom Bonded warehouse in Mexico -Strides Arcolab Limited has entered into a memorandum of understanding with BITS, Pilani for an ``off campus collaborative programme'. As part of the partnership, Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job. 2005 - Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets. -Strides Arcolab enters into an agreement for private placement issue - Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs -Strides acquires sterile manufacturing facility in Poland 2007 - Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets, an anti-HIV drug. Efavirenz, is the generic version of Bristol Myers Squibb's Sustiva, which helps in preventing the HIV virus from reproduction. - Strides Arcolab receives 2 more NDA approvals from US-FDA. 2008 - Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials. 2010 - Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been appointed as an Executive Director of the Company. 2011 -Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite -Strides announces First European Approval for Oncology Product -Strides Arcolab receives US FDA Nod to Commercialize First Liquid -StridesArcoL Update on acquisition of outstanding minority shareholding in Ascent Pharmahealth Limited -Strides Arcolab joins the Malaysian Bio-xcell Ecosystem 2012 -Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile -Strides Arcolab receives US FDA approval for Methotrexate Injection -Strides Arcolab Announces Health Canada Approval For Tobramycin Injection -Strides Arcolab acquires Sterile Formulations facility to expand core injectable biz -Strides collaborates with Gilead Sciences 2013 -Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet. - Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. - Strides announces WHO pre-qualification for Artemether Lumifantrine . -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology. -Strides Arcolab - Re-branding Biotech Business as 'Stelis'. -Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market. 2014 -- Medicines for Malaria Venture announces collaborations with Cipla and Strides. -Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. - Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. -Strides Arcolab receives US FDA approval for Buspirone Tablets. -Strides Arcolab receives US FDA approval for Calcitriol Softgel. -Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. -Strides Arcolab to acquire Shasun Pharma in all stock deal. 2015 -Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc -Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc, -Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India "Virso" -Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug -Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company. -Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia. -Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy -Strides Arcolab Ltd has changed from its present name "Strides Arcolab Limited" to "Strides Shasun Limited" 2016 -Strides Shasun updates on "Acquisition of seven brands from Johnson & Johnson". -Strides Shasun update on "Acquisition of CNS divisions of erstwhile Ranbaxy". -"Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia". -"Strides Shasun to acquire controlling stake in Universal Corporation, Kenya". -"Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet". - "Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore". 2017 -Strides Shasun bags approval for Acetazolamide tablets. -Strides bags approval for Omega-3-Acid Ethyl Esters capsules. -Strides Shasun gets USFDA nod to launch allergy drug in US. -Strides Shasun completes JV pact with Vivimed Labs. 2018 -Company name has changed to Strides Pharma Science Ltd. from Strides Shasun Ltd. -Strides gets USFDA nod for Polyethylene Glycol 3350 and Electrolytes for oral solution. -Strides' subsidiary inks pact with SUDA Pharmaceuticals for migraine drug. - Strides gets USFDA nod for Potassium Chloride Extended Release Tab. 2019 -Strides Pharma relaunches Ranitidine tablets in US. -Strides Pharma Science arm gets USFDA nod for drug to treat overactive bladder. -Strides Pharma acquires USFDA approved facility in the US. -Strides inks joint venture pact with China's Sihuan Pharma. 2020 -Strides Pharma Science gets USFDA nod for Prednisone tablets. -Strides Pharma Science gets USFDA nod for generic anti-bacterial capsules. -Strides arm receives EIR for its US facility. 2021 -Stelis Biopharma commissions its greenfield vaccine manufacturing facility at Bengaluru. -Strides, TLC partner to launch black fungus drug in India. -Strides Pharma arm receives USFDA nod for potassium chloride oral solution. -Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.

2002 -Board approves for the allotment of 210,955 shares of the company at Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd. -Zenith Pharmaceuticals Ltd acquires 71% shares through preferential issue route. -Board approves for the proposal of restructuring its Cram division by hiving off into two separate company under the provisions of the companies act. -Incorporates 'Strides Africa Ltd' at British Virgin Island with an authorised capital of US $ 200,000 as 100% wholly owned subsidiary. -Board decides to change the name of the company to 'Strides Arcolab (FA)' to reflect the change in the business focus and operations. 2003 -Nominates Mr Francis Pinto as the Director on the Board of the company. -Forges an exclusive co-operation alliance with the South Africa based drug manufacturer Aspen Pharmacare, mainly to share the product development expertise and quality systems. -Concludes the strategic development and manufacturing agreement with Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical products. -Changes in the Management: Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr Krishna Kumar Menon as COO. -Board approves for the reorganization of subsidiaries of the company and for write off of dimunition in value of investments made in subsidiaries by the company. -Strides inks MoU with Ribbon SRL for Cephalosporin 2004 -Major Fire occurs in Private Custom Bonded warehouse in Mexico -Strides Arcolab Limited has entered into a memorandum of understanding with BITS, Pilani for an ``off campus collaborative programme'. As part of the partnership, Strides has launched a new initiative called STEP (Strides Training and Education Plan) intend to offer their employees an opportunity to acquire a MS in Pharma Operations & Management while on the job. 2005 - Enters into an agreement with Mayne Pharma Business Unit of Australia based Mayne Group Ltd, to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets. -Strides Arcolab enters into an agreement for private placement issue - Strides Arcolab signs License Agreement with KV Pharma for exclusive marketing rights in the United States and Canada for 10 new generic drugs -Strides acquires sterile manufacturing facility in Poland 2007 - Strides Arcolab has got tentative permission from the United States Food and Drug Administration (USFDA) for Efavirenz tablets, an anti-HIV drug. Efavirenz, is the generic version of Bristol Myers Squibb's Sustiva, which helps in preventing the HIV virus from reproduction. - Strides Arcolab receives 2 more NDA approvals from US-FDA. 2008 - Strides Arcolab Ltd on March 19, 2008 announced its third ANDA approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials. 2010 - Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been appointed as an Executive Director of the Company. 2011 -Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite -Strides announces First European Approval for Oncology Product -Strides Arcolab receives US FDA Nod to Commercialize First Liquid -StridesArcoL Update on acquisition of outstanding minority shareholding in Ascent Pharmahealth Limited -Strides Arcolab joins the Malaysian Bio-xcell Ecosystem 2012 -Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile -Strides Arcolab receives US FDA approval for Methotrexate Injection -Strides Arcolab Announces Health Canada Approval For Tobramycin Injection -Strides Arcolab acquires Sterile Formulations facility to expand core injectable biz -Strides collaborates with Gilead Sciences 2013 -Strides Arcolab receives ANDA approval from USFDA for Tenofovir Disoproxil Fumarate and Emtricitabine Tablet. - Strides Arcolab announces US FDA approval for its Italian Semi-solids and Oinment facility. - Strides announces WHO pre-qualification for Artemether Lumifantrine . -StelisBiopharma and Pieris Forge Alliance for Novel Anticalin Therapeutics in Ophthalmology. -Strides Arcolab - Re-branding Biotech Business as 'Stelis'. -Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce Joint Venture to Develop Biosimilar Products for the Global Market. 2014 -- Medicines for Malaria Venture announces collaborations with Cipla and Strides. -Strides Arcolab makes strategic investment in Oncobiologics Inc., USA. - Strides partners with Gilead Sciences Inc, to bring Hepatitis C cure to 91 developing countries. -Strides Arcolab receives US FDA approval for Buspirone Tablets. -Strides Arcolab receives US FDA approval for Calcitriol Softgel. -Strides Arcolab acquires 'Raricap' and India Branded Generic Business of Bafna. -Strides Arcolab to acquire Shasun Pharma in all stock deal. 2015 -Strides Arcolab Ltd. has entered into an agreement with Fortuna Public Relations Pvt. Ltd., Delhi appointing them as Company's Public Relations Agenc -Strides Arcolab Ltd that it has entered into a licensing agreement with Gilead Sciences Inc, -Strides Arcolab Ltd has launched the generic drug Sofosbuvir in India "Virso" -Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350 -Strides Arcolab gets USFDA nod for HIV treatment drug -Strides Arcolab Ltd has approved the merger of Shasun Pharmaceuticals Ltd with the company. -Strides Arcolab has completed the Rs 1,910-crore acquisition of Aspen Pharmacare, Australia. -Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy -Strides Arcolab Ltd has changed from its present name "Strides Arcolab Limited" to "Strides Shasun Limited" 2016 -Strides Shasun updates on "Acquisition of seven brands from Johnson & Johnson". -Strides Shasun update on "Acquisition of CNS divisions of erstwhile Ranbaxy". -"Strides Shasun to acquire a strategic stake in Generic Partners Holdings, Australia". -"Strides Shasun to acquire controlling stake in Universal Corporation, Kenya". -"Strides Shasun receives USFDA Tentative Approval for Efavirenz Tablet". - "Strides Shasun announces successful completion of US FDA inspection at its Oral Dosage Facility in Bangalore". 2017 -Strides Shasun bags approval for Acetazolamide tablets. -Strides bags approval for Omega-3-Acid Ethyl Esters capsules. -Strides Shasun gets USFDA nod to launch allergy drug in US. -Strides Shasun completes JV pact with Vivimed Labs. 2018 -Company name has changed to Strides Pharma Science Ltd. from Strides Shasun Ltd. -Strides gets USFDA nod for Polyethylene Glycol 3350 and Electrolytes for oral solution. -Strides' subsidiary inks pact with SUDA Pharmaceuticals for migraine drug. - Strides gets USFDA nod for Potassium Chloride Extended Release Tab. 2019 -Strides Pharma relaunches Ranitidine tablets in US. -Strides Pharma Science arm gets USFDA nod for drug to treat overactive bladder. -Strides Pharma acquires USFDA approved facility in the US. -Strides inks joint venture pact with China's Sihuan Pharma. 2020 -Strides Pharma Science gets USFDA nod for Prednisone tablets. -Strides Pharma Science gets USFDA nod for generic anti-bacterial capsules. -Strides arm receives EIR for its US facility. 2021 -Stelis Biopharma commissions its greenfield vaccine manufacturing facility at Bengaluru. -Strides, TLC partner to launch black fungus drug in India. -Strides Pharma arm receives USFDA nod for potassium chloride oral solution. -Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.

Read More

Parent Organisation

Strides Pharma Science Ltd.

Founded

28/06/1990

Managing Director

NSE Symbol

STAREQ

FAQ

The current price of Strides Pharma Science Ltd is ₹ 587.55.

The 52-week high for Strides Pharma Science Ltd is ₹ 615.75 and the 52-week low is ₹ 581.05.

The market capitalization of Strides Pharma Science Ltd is currently ₹ 5415.02. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Strides Pharma Science Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Strides Pharma Science Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Strides Pharma Science Ltd shares.

The CEO of Strides Pharma Science Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT